Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

745.77 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

60 61 Next >

10 Bagger Stocks: Can You Find One? ↗

August 23, 2024

Finding 10 baggers is not easy, but it’s a worthwhile pursuit for long-term investors.

Via Talk Markets

What Analysts Are Saying About Regeneron Pharmaceuticals Stock ↗

August 23, 2024

Via Benzinga

Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment ↗

August 20, 2024

Regeneron Pharmaceuticals Inc. has received a setback as the Food and Drug Administration has declined its application for a blood cancer treatment.

Via Benzinga

Regeneron Provides Update on Biologics License Application for Linvoseltamab

August 20, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today ↗

August 20, 2024

Via Benzinga

Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector ↗

August 13, 2024

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today ↗

August 08, 2024

Via Benzinga

Analyst Ratings For Regeneron Pharmaceuticals ↗

August 02, 2024

Via Benzinga

Biotech Bull Market: 3 Ways To Play It ↗

August 20, 2024

Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.

Via Talk Markets

Topics Economy

Alphabet Turns Twenty ↗

August 19, 2024

Twenty years ago to the day, the company running the world's largest search engine went public. On August 19th, 2004, Alphabet shares IPO'd at a split-adjusted price of $2.13.

Via Talk Markets

7 Stocks That Usually Benefit From a Recession ↗

August 13, 2024

These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession.

Via InvestorPlace

3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown ↗

August 13, 2024

Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility.

Via InvestorPlace

3 Biotech Stocks With Promising Drug Pipelines: August 2024 ↗

August 08, 2024

The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.

Via InvestorPlace

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗

July 30, 2024

Via Benzinga

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today ↗

July 22, 2024

Via Benzinga

Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

August 07, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

3 Healthcare Stocks Positioned for Possible Market Outperformance ↗

August 07, 2024

While healthcare stocks might not be as shiny as they were in the pandemic era, these three could outperform the broader market.

Via InvestorPlace

Is Regeneron Pharmaceuticals Due for a Stock Split? ↗

August 03, 2024

Would a stock split help lead Regeneron Pharmaceuticals shares higher?

Via The Motley Fool

Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review ↗

August 02, 2024

Apple and Meta had strong results, while AI spending remains robust.

Via Investor's Business Daily

Topics Artificial Intelligence

Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗

July 19, 2024

Via Benzinga

Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs ↗

August 01, 2024

Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%...

Via Benzinga

US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? ↗

August 01, 2024

Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market...

Via Benzinga

Regeneron Stock Climbs After Strong Second-Quarter Performance ↗

August 01, 2024

A strong second-quarter performance lifted the already extended shares of the New York-based drug maker Regeneron.

Via Investor's Business Daily

Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November ↗

August 01, 2024

After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a...

Via Benzinga

Regeneron Reports Second Quarter 2024 Financial and Operating Results

August 01, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation

July 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Bull Market Buys: 2 Growth Stocks to Own for the Long Run ↗

July 27, 2024

These companies are no strangers to beating the market.

Via The Motley Fool

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand ↗

July 25, 2024

Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.

Via Benzinga

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients ↗

July 23, 2024

MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six...

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.